Antitumor activity of HER-2 inhibitors

This publication has 100 references indexed in Scilit:

• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Proceedings of the National Academy of Sciences, 2004
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
  Cancer Cell, 2004
• Monoclonal antibodies in the treatment of colorectal cancer
  European Journal Of Cancer, 2004
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004
• Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
  Cancer Cell, 2004
• Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
  Nature, 2003
• Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy
  The EMBO Journal, 2002
• NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer
  The EMBO Journal, 2000
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987